A buyer’s guide to CoA identity, assay, available chlorine, moisture, insolubles, test methods and a controlled response to failed lots.
A Certificate of Analysis should connect one identified batch to an agreed specification, named test methods, actual results and an authorised release decision. It is evidence about the tested sample, not a substitute for supplier qualification, representative sampling or incoming inspection.
Before reading the chemistry, match the CoA to the purchase and physical lot. Check product and grade, manufacturer, manufacturing site where stated, batch or lot number, manufacture or test date, package marks, certificate number and issuing laboratory. Resolve any mismatch before releasing stock.
The World Health Organization's model CoA says a certificate normally lists the tests performed on a particular sample, results obtained, acceptance criteria and whether the sample complies. It recommends identifiers for the certificate and pages, the laboratory, sample, batch, dates, methods, limits, results, conclusion and approving signature.[1]
A copied typical analysis, sales specification or blank template is not a batch CoA. Watch for results repeated identically across many lots, missing units, “passes” where a numerical result was agreed, or a certificate created before the stated manufacturing date. These are reasons to query, not proof of wrongdoing.
Every reported characteristic has three parts: the contractual acceptance limit, the method used and the result. A number is not interpretable without units and basis. “Moisture 0.5” is incomplete unless the certificate identifies percentage basis and method.
FAO and WHO guidance describes specifications as quality criteria supported by appropriate test methods and highlights validated, robust testing as the means of distinguishing acceptable from poor-quality material.[2] The buyer and supplier should therefore agree the specification version and methods before ordering. A method change can shift results even when the material has not changed.
Check whether limits are minimum, maximum or a range. Confirm rounding rules and significant figures if a result sits near a boundary. Do not silently reinterpret a supplier result using extra decimal places or a different basis.
Assay quantifies the stated principal substance under the named analytical method. It may be expressed as mass fraction, concentration or on a dry basis. Compare like with like: as-received and dry-basis values answer different questions, and solution grades require a clear mass or volume basis.
Available chlorine is an oxidising-capacity expression used for chlorine-releasing chemicals; it is not simply the elemental chlorine mass shown by a compositional formula. For calcium hypochlorite, sodium hypochlorite and chlorinated isocyanurates, the purchase specification should name the method and basis. Treat any conversion between assay and available chlorine as a technical method question and document its basis.
A result above one minimum does not settle the complete acceptance decision. Review every limit in the agreed specification. Conversely, a low available-chlorine result may arise from degradation, moisture ingress, sampling or analytical error; route the discrepancy through the agreed technical investigation rather than treating it as an automatic conversion issue.
Moisture can dilute active content, affect flow and indicate storage or packaging exposure. Read it alongside assay and the calculation basis. For hygroscopic solids, the sampling and handling interval can influence the measurement, so the method and sealed-sample practice matter.
Insolubles describe material not dissolved under defined test conditions. The result depends on solvent, concentration, temperature, time, filtration and reporting basis. It can flag contamination or formulation issues, but “insolubles” without a method is too vague for a defensible acceptance decision.
Also review appearance, pH where specified, particle size, bulk density, relevant impurities and package weight. The right panel depends on the product and process. Avoid adding tests that are not tied to a risk or acceptance criterion, but do not omit critical impurities merely because the headline assay passes.
A precise test on an unrepresentative sample can give a misleading answer. Define who samples, from how many packages or points, using what clean equipment, how the sample is sealed, and how chain of custody is recorded. Preserve a retain sample where the quality agreement requires it.
Incoming verification should be risk-based. New sources, changed sites, prior failures and critical applications may justify stronger identity or full-specification testing. Established performance may support a different plan, but relying on supplier CoAs should be a documented quality decision rather than an assumption.
Laboratory competence and method suitability matter. WHO's model expects subcontracted tests to be identified and calls for sampling procedures to be referenced when relevant to interpretation.[1] Ask who actually performed each test and whether the result is manufacturer-generated or from an independent laboratory.
US FDA laboratory guidance, although written for pharmaceutical production, states a useful investigation principle: an out-of-specification result includes results outside established specifications and should be investigated; averaging or repeated testing must not be used to conceal variability.[3] Chemical buyers can apply that disciplined logic without claiming the pharmaceutical guidance governs their product.
Use the agreed release process even when supply is urgent, and route shortages through the approved continuity plan. See dual sourcing and supply resilience.
Reviewed on . Next review due .